

REFERENCES USED IN ALGORITHMS FOR THE TREATMENT OF PERSONS WITH CROHN'S DISEASE

1. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, Sultan S, Cohen BL, Chachu K *et al*: **AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease**. *Gastroenterology* 2021, **160**(7):2496-2508.
2. Lichtenstein GR, Loftus EV, Isaacs KL, Regueiro MD, Gerson LB, Sands BE: **ACG Clinical Guideline: Management of Crohn's Disease in Adults**. *Am J Gastroenterol* 2018, **113**(4):481-517.
3. Lamb CA, Kennedy NA, Raine T, Hendy PA, Smith PJ, Limdi JK, Hayee B, Lomer MCE, Parkes GC, Selinger C *et al*: **British Society of Gastroenterology consensus guidelines on the management of inflammatory bowel disease in adults**. *Gut* 2019, **68**(Suppl 3):s1-s106.
4. National Institute for Health and Care Excellence: **Crohn's disease management in adults, children and young people [NICE Guideline CG152]**. In.; 2012.
5. Panaccione R, Steinhart AH, Bressler B, Khanna R, Marshall JK, Targownik L, Afif W, Bitton A, Borgaonkar M, Chauhan U *et al*: **Canadian Association of Gastroenterology Clinical Practice Guideline for the Management of Luminal Crohn's Disease**. *Clin Gastroenterol Hepatol* 2019, **17**(9):1680-1713.
6. National Institute for Health and Care Excellence: **Crohn's disease: management [NICE GuidelineNG129]**. In.; 2019.
7. National Institute for Health and Care Excellence: **Crohn's disease: management. Evidence review for post-surgical maintenance of remission [NICE GuidelineNG129]**. In.; 2019.
8. Lim WC, Wang Y, MacDonald JK, Hanauer S: **Aminosalicylates for induction of remission or response in Crohn's disease**. *Cochrane Database Syst Rev* 2016, **7**:Cd008870.
9. Swen JJ, Nijenhuis M, de Boer A, Grandia L, Maitland-van der Zee AH, Mulder H, Rongen GA, van Schaik RH, Schalekamp T, Touw DJ *et al*: **Pharmacogenetics: from bench to byte--an update of guidelines**. *Clin Pharmacol Ther* 2011, **89**(5):662-673.
10. **Dutch Guidelines**. [<https://www.knmp.nl/downloads/pharmacogenetic-recommendations-august-2019.pdf>]
11. Schaeffeler E, Jaeger SU, Klumpp V, Yang JJ, Igel S, Hinze L, Stanulla M, Schwab M: **Impact of NUDT15 genetics on severe thiopurine-related hematotoxicity in patients with European ancestry**. *Genet Med* 2019, **21**(9):2145-2150.
12. Relling MV, Gardner EE, Sandborn WJ, Schmiegelow K, Pui CH, Yee SW, Stein CM, Carrillo M, Evans WE, Hicks JK *et al*: **Clinical pharmacogenetics implementation consortium guidelines for thiopurine methyltransferase genotype and thiopurine dosing: 2013 update**. *Clin Pharmacol Ther* 2013, **93**(4):324-325.
13. Relling MV, Schwab M, Whirl-Carrillo M, Suarez-Kurtz G, Pui CH, Stein CM, Moyer AM, Evans WE, Klein TE, Antillon-Klussmann FG *et al*: **Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update**. *Clin Pharmacol Ther* 2019, **105**(5):1095-1105.

14. Birdwell KA, Decker B, Barbarino JM, Peterson JF, Stein CM, Sadee W, Wang D, Vinks AA, He Y, Swen JJ *et al*: **Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing**. *Clin Pharmacol Ther* 2015, **98**(1):19-24.
15. Iannaccone CK, Lee YC, Cui J, Frits ML, Glass RJ, Plenge RM, Solomon DH, Weinblatt ME, Shadick NA: **Using genetic and clinical data to understand response to disease-modifying anti-rheumatic drug therapy: data from the Brigham and Women's Hospital Rheumatoid Arthritis Sequential Study**. *Rheumatology (Oxford)* 2011, **50**(1):40-46.
16. Lee YC, Cui J, Costenbader KH, Shadick NA, Weinblatt ME, Karlson EW: **Investigation of candidate polymorphisms and disease activity in rheumatoid arthritis patients on methotrexate**. *Rheumatology (Oxford)* 2009, **48**(6):613-617.
17. Lacruz-Guzman D, Torres-Moreno D, Pedrero F, Romero-Cara P, Garcia-Tercero I, Trujillo-Santos J, Conesa-Zamora P: **Influence of polymorphisms and TNF and IL1beta serum concentration on the infliximab response in Crohn's disease and ulcerative colitis**. *Eur J Clin Pharmacol* 2013, **69**(3):431-438.
18. Tong Q, Zhao L, Qian XD, Zhang LL, Xu X, Dai SM, Cai Q, Zhao DB: **Association of TNF-alpha polymorphism with prediction of response to TNF blockers in spondyloarthritis and inflammatory bowel disease: a meta-analysis**. *Pharmacogenomics* 2013, **14**(14):1691-1700.
19. Song GG, Seo YH, Kim JH, Choi SJ, Ji JD, Lee YH: **Association between TNF-alpha (-308 A/G, -238 A/G, -857 C/T) polymorphisms and responsiveness to TNF-alpha blockers in spondyloarthropathy, psoriasis and Crohn's disease: a meta-analysis**. *Pharmacogenomics* 2015, **16**(12):1427-1437.
20. Netz U, Carter JV, Eichenberger MR, Dryden GW, Pan J, Rai SN, Galandiuk S: **Genetic polymorphisms predict response to anti-tumor necrosis factor treatment in Crohn's disease**. *World J Gastroenterol* 2017, **23**(27):4958-4967.
21. Tavares M, de Lima C, Fernandes W, Martinelli V, de Lucena M, Lima F, Telles A, Brandao L, de Melo Junior M: **Tumour necrosis factor-alpha (-308G/A) promoter polymorphism is associated with ulcerative colitis in Brazilian patients**. *Int J Immunogenet* 2016, **43**(6):376-382.
22. Zeng Z, Duan Z, Zhang T, Wang S, Li G, Gao J, Ye D, Xu S, Xu J, Zhang L *et al*: **Association between tumor necrosis factor-alpha (TNF-alpha) promoter -308 G/A and response to TNF-alpha blockers in rheumatoid arthritis: a meta-analysis**. *Mod Rheumatol* 2013, **23**(3):489-495.
23. Daien CI, Fabre S, Rittore C, Soler S, Daien V, Tejedor G, Cadart D, Molinari N, Daures JP, Jorgensen C *et al*: **TGF beta1 polymorphisms are candidate predictors of the clinical response to rituximab in rheumatoid arthritis**. *Joint Bone Spine* 2012, **79**(5):471-475.
24. Maxwell JR, Potter C, Hyrich KL, Barton A, Worthington J, Isaacs JD, Morgan AW, Wilson AG: **Association of the tumour necrosis factor-308 variant with differential response to anti-TNF agents in the treatment of rheumatoid arthritis**. *Hum Mol Genet* 2008, **17**(22):3532-3538.
25. Marotte H, Arnaud B, Diasparra J, Zrioual S, Miossec P: **Association between the level of circulating bioactive tumor necrosis factor alpha and the tumor necrosis factor alpha gene polymorphism at -308 in patients with rheumatoid arthritis treated with a tumor necrosis factor alpha inhibitor**. *Arthritis Rheum* 2008, **58**(5):1258-1263.

26. Miceli-Richard C, Comets E, Verstuyft C, Tamouza R, Loiseau P, Ravaud P, Kupper H, Becquemont L, Charron D, Mariette X: **A single tumour necrosis factor haplotype influences the response to adalimumab in rheumatoid arthritis.** *Ann Rheum Dis* 2008, **67**(4):478-484.
27. Guis S, Balandraud N, Bouvenot J, Auger I, Toussirot E, Wendling D, Mattei JP, Nogueira L, Mugnier B, Legeron P *et al*: **Influence of -308 A/G polymorphism in the tumor necrosis factor alpha gene on etanercept treatment in rheumatoid arthritis.** *Arthritis Rheum* 2007, **57**(8):1426-1430.
28. Seitz M, Wirthmuller U, Moller B, Villiger PM: **The -308 tumour necrosis factor-alpha gene polymorphism predicts therapeutic response to TNFalpha-blockers in rheumatoid arthritis and spondyloarthritis patients.** *Rheumatology (Oxford)* 2007, **46**(1):93-96.
29. Cuchacovich M, Soto L, Edwardes M, Gutierrez M, Llanos C, Pacheco D, Sabugo F, Alamo M, Fuentealba C, Villanueva L *et al*: **Tumour necrosis factor (TNF)alpha -308 G/G promoter polymorphism and TNFalpha levels correlate with a better response to adalimumab in patients with rheumatoid arthritis.** *Scand J Rheumatol* 2006, **35**(6):435-440.
30. Fonseca JE, Carvalho T, Cruz M, Nero P, Sobral M, Mourao AF, Cavaleiro J, Ligeiro D, Abreu I, Carmo-Fonseca M *et al*: **Polymorphism at position -308 of the tumour necrosis factor alpha gene and rheumatoid arthritis pharmacogenetics.** *Ann Rheum Dis* 2005, **64**(5):793-794.
31. Mugnier B, Balandraud N, Darque A, Roudier C, Roudier J, Reviron D: **Polymorphism at position -308 of the tumor necrosis factor alpha gene influences outcome of infliximab therapy in rheumatoid arthritis.** *Arthritis Rheum* 2003, **48**(7):1849-1852.
32. Padyukov L, Lampa J, Heimbürger M, Ernestam S, Cederholm T, Lundkvist I, Andersson P, Hermansson Y, Harju A, Klareskog L *et al*: **Genetic markers for the efficacy of tumour necrosis factor blocking therapy in rheumatoid arthritis.** *Ann Rheum Dis* 2003, **62**(6):526-529.
33. Sutiman N, Chen S, Ling KL, Chuah SW, Leong WF, Nadiger V, Tjai M, Choon Kong CS, Schwender BJ, Chan W *et al*: **Predictive role of NUDT15 variants on thiopurine-induced myelotoxicity in Asian inflammatory bowel disease patients.** *Pharmacogenomics* 2018, **19**(1):31-43.
34. Liu YP, Xu HQ, Li M, Yang X, Yu S, Fu WL, Huang Q: **Association between Thiopurine S-Methyltransferase Polymorphisms and Azathioprine-Induced Adverse Drug Reactions in Patients with Autoimmune Diseases: A Meta-Analysis.** *PLoS One* 2015, **10**(12):e0144234.
35. Kakuta Y, Kawai Y, Okamoto D, Takagawa T, Ikeya K, Sakuraba H, Nishida A, Nakagawa S, Miura M, Toyonaga T *et al*: **NUDT15 codon 139 is the best pharmacogenetic marker for predicting thiopurine-induced severe adverse events in Japanese patients with inflammatory bowel disease: a multicenter study.** *J Gastroenterol* 2018, **53**(9):1065-1078.
36. Kim HS, Cheon JH, Jung ES, Park J, Aum S, Park SJ, Eun S, Lee J, Ruther U, Yeo GSH *et al*: **A coding variant in FTO confers susceptibility to thiopurine-induced leukopenia in East Asian patients with IBD.** *Gut* 2017, **66**(11):1926-1935.
37. Wang HH, He Y, Wang HX, Liao CL, Peng Y, Tao LJ, Zhang W, Yang HX: **Comparison of TPMT and NUDT15 polymorphisms in Chinese patients with inflammatory bowel disease.** *World J Gastroenterol* 2018, **24**(8):941-948.

38. Fangbin Z, Xiang G, Liang D, Hui L, Xuoding W, Baili C, Huichang B, Yinglian X, Peng C, Lizi Z *et al*: **Prospective Evaluation of Pharmacogenomics and Metabolite Measurements upon Azathioprine Therapy in Inflammatory Bowel Disease: An Observational Study.** *Medicine (Baltimore)* 2016, **95**(15):e3326.
39. Odahara S, Uchiyama K, Kubota T, Ito Z, Takami S, Kobayashi H, Saito K, Koido S, Ohkusa T: **A Prospective Study Evaluating Metabolic Capacity of Thiopurine and Associated Adverse Reactions in Japanese Patients with Inflammatory Bowel Disease (IBD).** *PLoS One* 2015, **10**(9):e0137798.
40. Coenen MJ, de Jong DJ, van Marrewijk CJ, Derijks LJ, Vermeulen SH, Wong DR, Klungel OH, Verbeek AL, Hooymans PM, Peters WH *et al*: **Identification of Patients With Variants in TPMT and Dose Reduction Reduces Hematologic Events During Thiopurine Treatment of Inflammatory Bowel Disease.** *Gastroenterology* 2015, **149**(4):907-917 e907.
41. Carvalho AT, Esberard BC, Froes RS, Rapozo DC, Grinman AB, Simao TA, Santos JC, Carneiro AJ, Ribeiro-Pinto LF, de Souza HS: **Thiopurine-methyltransferase variants in inflammatory bowel disease: prevalence and toxicity in Brazilian patients.** *World J Gastroenterol* 2014, **20**(12):3327-3334.
42. Hlavaty T, Batovsky M, Balakova D, Pav I, Celec P, Gregus M, Zakuciova M, Hlista M, Horakova M, Desatova B *et al*: **The impact of thiopurine-S-methyltransferase genotype on the adverse drug reactions to azathioprine in patients with inflammatory bowel diseases.** *Bratisl Lek Listy* 2013, **114**(4):199-205.
43. Gazouli M, Pachoula I, Panayotou I, Chouliaras G, Anagnou NP, Chroussos G, Roma E: **Thiopurine methyltransferase genotype and thiopurine S-methyltransferase activity in Greek children with inflammatory bowel disease.** *Ann Gastroenterol* 2012, **25**(3):249-253.
44. Zabala-Fernandez W, Barreiro-de Acosta M, Echarri A, Carpio D, Lorenzo A, Castro J, Martinez-Ares D, Pereira S, Martin-Granizo I, Corton M *et al*: **A pharmacogenetics study of TPMT and ITPA genes detects a relationship with side effects and clinical response in patients with inflammatory bowel disease receiving Azathioprine.** *J Gastrointestin Liver Dis* 2011, **20**(3):247-253.
45. Gearry RB, Barclay ML, Roberts RL, Harraway J, Zhang M, Pike LS, George PM, Florkowski CM: **Thiopurine methyltransferase and 6-thioguanine nucleotide measurement: early experience of use in clinical practice.** *Intern Med J* 2005, **35**(10):580-585.
46. Higgs JE, Payne K, Roberts C, Newman WG: **Are patients with intermediate TPMT activity at increased risk of myelosuppression when taking thiopurine medications?** *Pharmacogenomics* 2010, **11**(2):177-188.
47. Dong XW, Zheng Q, Zhu MM, Tong JL, Ran ZH: **Thiopurine S-methyltransferase polymorphisms and thiopurine toxicity in treatment of inflammatory bowel disease.** *World J Gastroenterol* 2010, **16**(25):3187-3195.
48. Yin D, Xia X, Zhang J, Zhang S, Liao F, Zhang G, Zhang Y, Hou Q, Yang X, Wang H *et al*: **Impact of NUDT15 polymorphisms on thiopurines-induced myelotoxicity and thiopurines tolerance dose.** *Oncotarget* 2017, **8**(8):13575-13585.
49. van Gennep S, Konte K, Meijer B, Heymans MW, D'Haens GR, Lowenberg M, de Boer NKH: **Systematic review with meta-analysis: risk factors for thiopurine-induced leukopenia in IBD.** *Aliment Pharmacol Ther* 2019, **50**(5):484-506.

50. Cargnin S, Genazzani AA, Canonico PL, Terrazzino S: **Diagnostic accuracy of NUDT15 gene variants for thiopurine-induced leukopenia: a systematic review and meta-analysis.** *Pharmacol Res* 2018, **135**:102-111.
51. Fei X, Shu Q, Hua BZ, Wang SY, Chen ZY, Ge WH, Fang Y: **NUDT15 R139C variation increases the risk of azathioprine-induced toxicity in Chinese subjects: Case report and literature review.** *Medicine (Baltimore)* 2018, **97**(17):e0301.
52. Lee JH, Kim TJ, Kim ER, Hong SN, Chang DK, Choi LH, Woo HI, Lee SY, Kim YH: **Measurements of 6-thioguanine nucleotide levels with TPMT and NUDT15 genotyping in patients with Crohn's disease.** *PLoS One* 2017, **12**(12):e0188925.
53. Yi ES, Choi YB, Choi R, Lee NH, Lee JW, Yoo KH, Sung KW, Lee SY, Koo HH: **NUDT15 Variants Cause Hematopoietic Toxicity with Low 6-TGN Levels in Children with Acute Lymphoblastic Leukemia.** *Cancer Res Treat* 2018, **50**(3):872-882.
54. Asada A, Nishida A, Shioya M, Imaeda H, Inatomi O, Bamba S, Kito K, Sugimoto M, Andoh A: **NUDT15 R139C-related thiopurine leukocytopenia is mediated by 6-thioguanine nucleotide-independent mechanism in Japanese patients with inflammatory bowel disease.** *J Gastroenterol* 2016, **51**(1):22-29.
55. Yang F, Gu B, Zhang L, Xuan J, Luo H, Zhou P, Zhu Q, Yan S, Chen SA, Cao Z *et al*: **HLA-B*13:01 is associated with salazosulfapyridine-induced drug rash with eosinophilia and systemic symptoms in Chinese Han population.** *Pharmacogenomics* 2014, **15**(11):1461-1469.
56. Wiese MD, Alotaibi N, O'Doherty C, Sorich MJ, Suppiah V, Cleland LG, Proudman SM: **Pharmacogenomics of NAT2 and ABCG2 influence the toxicity and efficacy of sulphasalazine containing DMARD regimens in early rheumatoid arthritis.** *Pharmacogenomics J* 2014, **14**(4):350-355.
57. Konvinse KC, Trubiano JA, Pavlos R, James I, Shaffer CM, Bejan CA, Schutte RJ, Ostrov DA, Pilkinton MA, Rosenbach M *et al*: **HLA-A*32:01 is strongly associated with vancomycin-induced drug reaction with eosinophilia and systemic symptoms.** *J Allergy Clin Immunol* 2019, **144**(1):183-192.
58. Sansone S, Rottensteiner J, Stocker J, Rosanelli C, Wiedermann CJ: **Ciprofloxacin-induced acute haemolytic anaemia in a patient with glucose-6-phosphate dehydrogenase Mediterranean deficiency: a case report.** *Ann Hematol* 2010, **89**(9):935-937.
59. Loft ND, Skov L, Iversen L, Gniadecki R, Dam TN, Brandslund I, Hoffmann HJ, Andersen MR, Dessau RB, Bergmann AC *et al*: **Associations between functional polymorphisms and response to biological treatment in Danish patients with psoriasis.** *Pharmacogenomics J* 2018, **18**(3):494-500.
60. Tang HL, Xie HG, Yao Y, Hu YF: **Lower tacrolimus daily dose requirements and acute rejection rates in the CYP3A5 nonexpressers than expressers.** *Pharmacogenet Genomics* 2011, **21**(11):713-720.
61. Terrazzino S, Quaglia M, Stratta P, Canonico PL, Genazzani AA: **The effect of CYP3A5 6986A>G and ABCB1 3435C>T on tacrolimus dose-adjusted trough levels and acute rejection rates in renal transplant patients: a systematic review and meta-analysis.** *Pharmacogenet Genomics* 2012, **22**(8):642-645.
62. Rojas L, Neumann I, Herrero MJ, Boso V, Reig J, Poveda JL, Megias J, Bea S, Alino SF: **Effect of CYP3A5*3 on kidney transplant recipients treated with tacrolimus: a systematic review and meta-analysis of observational studies.** *The pharmacogenomics journal* 2015, **15**(1):38-48.

63. Zong YP, Wang ZJ, Zhou WL, Zhou WM, Ma TL, Huang ZK, Zhao CC, Xu Z, Tan RY, Gu M: **Effects of CYP3A5 polymorphisms on tacrolimus pharmacokinetics in pediatric kidney transplantation: a systematic review and meta-analysis of observational studies.** *World J Pediatr* 2017, **13**(5):421-426.
64. Hendijani F, Azarpira N, Kaviani M: **Effect of CYP3A5*1 expression on tacrolimus required dose for transplant pediatrics: A systematic review and meta-analysis.** *Pediatr Transplant* 2018:e13248.
65. Oetting WS, Wu B, Schladt DP, Guan W, Rimmel RP, Dorr C, Mannon RB, Matas AJ, Israni AK, Jacobson PA: **Attempted validation of 44 reported SNPs associated with tacrolimus troughs in a cohort of kidney allograft recipients.** *Pharmacogenomics* 2018, **19**(3):175-184.
66. Zheng S, Tasnif Y, Hebert MF, Davis CL, Shitara Y, Calamia JC, Lin YS, Shen DD, Thummel KE: **CYP3A5 gene variation influences cyclosporine A metabolite formation and renal cyclosporine disposition.** *Transplantation* 2013, **95**(6):821-827.
67. Santoro A, Felipe CR, Tedesco-Silva H, Medina-Pestana JO, Struchiner CJ, Ojopi EB, Suarez-Kurtz G: **Pharmacogenetics of calcineurin inhibitors in Brazilian renal transplant patients.** *Pharmacogenomics* 2011, **12**(9):1293-1303.
68. Zhu HJ, Yuan SH, Fang Y, Sun XZ, Kong H, Ge WH: **The effect of CYP3A5 polymorphism on dose-adjusted cyclosporine concentration in renal transplant recipients: a meta-analysis.** *Pharmacogenomics J* 2011, **11**(3):237-246.
69. Lunde I, Bremer S, Midtvedt K, Mohebi B, Dahl M, Bergan S, Asberg A, Christensen H: **The influence of CYP3A, PP2A, and POR genetic variants on the pharmacokinetics of tacrolimus and cyclosporine in renal transplant recipients.** *Eur J Clin Pharmacol* 2014, **70**(6):685-693.
70. Garcia M, Macias RM, Cubero JJ, Benitez J, Caravaca F, Gervasini G: **ABCB1 polymorphisms are associated with cyclosporine-induced nephrotoxicity and gingival hyperplasia in renal transplant recipients.** *Eur J Clin Pharmacol* 2013, **69**(3):385-393.
71. Moes DJ, Swen JJ, den Hartigh J, van der Straaten T, van der Heide JJ, Sanders JS, Bemelman FJ, de Fijter JW, Guchelaar HJ: **Effect of CYP3A4*22, CYP3A5*3, and CYP3A Combined Genotypes on Cyclosporine, Everolimus, and Tacrolimus Pharmacokinetics in Renal Transplantation.** *CPT: pharmacometrics & systems pharmacology* 2014, **3**:e100.
72. Tao XR, Xia XY, Zhang J, Tong LY, Zhang W, Zhou X, Liu ZH, Song HT: **CYP3A4 *18B and CYP3A5 *3 polymorphisms contribute to pharmacokinetic variability of cyclosporine among healthy Chinese subjects.** *Eur J Pharm Sci* 2015, **76**:238-244.
73. Debette-Gratien M, Woillard JB, Picard N, Sebah M, Loustaud-Ratti V, Sautereau D, Samuel D, Marquet P: **Influence of Donor and Recipient CYP3A4, CYP3A5, and ABCB1 Genotypes on Clinical Outcomes and Nephrotoxicity in Liver Transplant Recipients.** *Transplantation* 2016, **100**(10):2129-2137.
74. Sun B, Guo Y, Gao J, Shi W, Fan G, Li X, Qiu J, Qin Y, Liu G: **Influence of CYP3A and ABCB1 polymorphisms on cyclosporine concentrations in renal transplant recipients.** *Pharmacogenomics* 2017, **18**(16):1503-1513.

75. Gervasini G, Garcia-Pino G, Vergara E, Mota-Zamorano S, Garcia-Cerrada M, Luna E: **CYP3A genotypes of donors but not those of the patients increase the risk of acute rejection in renal transplant recipients on calcineurin inhibitors: a pilot study.** *Eur J Clin Pharmacol* 2018, **74**(1):53-60.
76. Pharmascience Inc: **pms-SULFASALAZINE.** In: *CA Product Monograph.* Montreal, QC; 2020.
77. Actavis Pharma Inc: **Sulfasalazine.** In: *US Product Monograph.* Parsippany, NJ; 2022.
78. Pfizer Laboratories Div Pfizer Inc: **Azulfidine (sulfasalazine).** In: *US Product Monograph.* New York, NY; 2021.
79. Youngster I, Arcavi L, Schechmaster R, Akayzen Y, Popliski H, Shimonov J, Beig S, Berkovitch M: **Medications and glucose-6-phosphate dehydrogenase deficiency: an evidence-based review.** *Drug safety* 2010, **33**(9):713-726.
80. Herman J, Ben-Meir S: **Overt hemolysis in patients with glucose-6-phosphate dehydrogenase deficiency: a survey in general practice.** *Israel journal of medical sciences* 1975, **11**(4):340-346.
81. Pfizer: **Sulfasalazine.** In: *Health Canada Product Monograph.* Kirkland, Quebec; 2019.
82. Pharmacia and Upjohn Company: **Sulfasalazine.** In: *FDA Product Monograph.* 2018.
83. Lindblad A RL, Jensen B: **Inflammatory Bowel Disease: Drug Comparison Chart.** In: *RxFiles Drug Comparison Charts.* 11th ed edn. Saskatoon Health Region; 2019: 65-66.
84. Jensen B: **Rheumatoid Arthritis Treatment Chart.** In: *RxFiles.* vol. 11th ed. Saskatoon, SK: Saskatoon Health Region; 2018.
85. Division of Nephrology & Hypertension: **Adult Drug Book.** In. Louisville, KY: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
86. Tillotts Pharma GmbH: **Entocort (budesonide).** In: *CA Product Monograph.* Burlington, ON; 2021.
87. Amneal Pharmaceuticals LLC: **Budesonide capsule delayed release.** In: *US Product Monograph.* Bridgewater, NJ; 2021.
88. Ferring Pharmaceuticals Inc.: **Ortikos (budesonide capsule).** In: *US Product Monograph.* Parsippany, NJ; 2022.
89. TevaCanada: **Teva-Budesonide suspension for inhalation.** In: *CA monograph.* 2017.
90. AstraZeneca: **Budesonide Pulmicort Respules.** In: *US monograph.* 12/2018 edn. Wilmington, DE: AstraZeneca Pharmaceuticals; 2018.
91. AstraZeneca Canada Inc.: **Pulmicort Turbuhaler (budesonide).** In: *CA Product Monograph.* Mississauga, ON; 2017.
92. AstraZeneca: **Budesonide (PulmicortFlexhaler).** In: *US monograph.* 12/2018 edn. Wilmington DE: AstraZeneca Pharmaceuticals LP; 2018.

93. Inc. AC: **Pulmicort Nebuamp budesonide suspension for inhalation**. In: *Product Monograph*. Mississauga, Ontario: AstraZeneca Canada Inc.; 2013.
94. AstraZeneca: **Pulmicort Flexhaler (budesonide)**. In: *USA Monograph*. Wilmington, DE: AstraZeneca Pharmaceuticals LP; 2016.
95. CPhA: **Corticosteroids: Inhaled**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2016.
96. Tillotts Pharma GmbH: **Entocort (budesonide)**. In: *CA Product Monograph*. Dundas, ON; 2019.
97. Ferring Inc: **Cortiment MMX (budesonide)**. In: *CA Product Monograph*. North York, Ontario; 2016.
98. Paddock Laboratories LLC: **Entocort EC (budesonide)**. In: *US Product Monograph*. Allegan, MI; 2019.
99. Cosmo SPA: **Uceris (budesonide)**. In: *US Product Monograph*. Milan, Italy; 2020.
100. **Adult Drug Book**. In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.
101. Taro Pharmaceuticals Inc.: **Taro-Budesonide (Budesonide Suspension for Inhalation)**. In: *CA Product Monograph*. Brampton, ON; 2019.
102. AstraZeneca Pharmaceuticals LP: **Pulmicort Flexhaler (budesonide aerosol, powder)**. In: *US Product Monograph*. Wilmington, DE; 2019.
103. Nephron Pharmaceuticals Corporation: **Budesonide inhalant**. In: *US Product Monograph*. West Columbia, SC; 2021.
104. Miravittles M, Soler-Cataluna JJ, Calle M, Molina J, Almagro P, Quintano JA, Trigueros JA, Cosio BG, Casanova C, Antonio Riesco J *et al*: **Spanish Guidelines for Management of Chronic Obstructive Pulmonary Disease (GesEPOC) 2017. Pharmacological Treatment of Stable Phase**. *Archivos de bronconeumologia* 2017, **53**(6):324-335.
105. Guidelines B: **Chronic Obstructive Pulmonary Disease (COPD): Diagnosis and management**. In. Edited by Committee GPA; 2017.
106. McIvor RA: **Chronic Obstructive Pulmonary Disease**. In: *therapeutics*. Edited by Jean G. Ottawa (ON): Canadian Pharmacists Association; 2017.
107. RxFiles: **COPD: Drug Comparison Chart**. In., Jan 2018 edn; 2018.
108. Teva Canada Limited: **Teva-Prednisone**. In: *CA Product Monograph*. Toronto, ON; 2020.
109. Aurobindo Pharma Limited: **Prednisone**. In: *US Product Monograph*. East Windsor, NJ; 2022.
110. AA Pharma Inc: **Winpred (prednisone)**. In: *CA Product Monograph*. Vaughan, Ontario; 2018.
111. Horizon Pharma Inc: **Rayos (prednisone)**. In: *US Product Monograph*. Lake Forest, IL; 2019.
112. **Adult Drug Book** In.: University of Louisville, Division of Nephrology, Kidney Disease Program; 2020.

113. Inc A: **Apo-Prednisone prednisone tablets USP**. In: *Product Monograph*. Toronto, Ontario: Apotex Inc.; 2015.
114. Mclvor R: **Chronic Obstructive Pulmonary Disease**. In: *Therapeutics*. Edited by Jean G. Ottawa (ON): Canadian Pharmacists Association; 2019.
115. Horizon Pharma Inc: **Rayos (prednisone)**. In: *US Product Monograph*. Lake Forest, IL; 2017.
116. Mclvor R: **Chronic Obstructive Pulmonary Disease**. In: *Therapeutics*. Edited by Jean G. Ottawa (ON): Canadian Pharmacists Association; 2015.
117. Sanford: **Bronchitis, Chronic with Acute Exacerbation**. In: *Sanford Guide Web Edition*. Sperryville, VA: Antimicrobial Therapy Inc; 2019.
118. NICE: **Chronic obstructive pulmonary disease in over 16s: diagnosis and management**. 2018.
119. GOLD: **Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease 2020 report**. In.; 2020.
120. CPhA: **Corticosteroids: Systemic**. In: *CPhA Monograph*. Canadian Pharmacists Association; 2016.
121. APOTEX INC.: **Apo-Prednisone**. In: *Prescribing Information*. Toronto, Ontario: Apotex Inc.; 2015.
122. Horizon: **Prednisone**. In: *US Monograph*. 09/2017 edn. Lake Forest, IL: Horizon Pharma; 2017.
123. NICE: **Osteoarthritis**. In: *NICE Guideline*. vol. NG177. London: National Institute for Health and Care Excellence; 2014.
124. Aspen Pharmacare Canada Inc: **Imuran (azathioprine)**. In: *CA Product Monograph*. Oakville, ON; 2022.
125. Ascend Laboratories: **Azathioprine**. In: *US Product Monograph*. Parsippany, NJ; 2022.
126. Aspen Pharmacare Canada Inc: **Imuran (azathioprine)**. In: *CA Product Monograph*. Oakville, ON; 2019.
127. Sebelo Pharmaceuticals Inc: **Imuran (azathioprine)**. In: *US Product Monograph*. Roswell, GA; 2019.
128. Teva Canada Limited: **Purinnethol (mercaptopurine)**. In: *CA Product Monograph*. Toronto, ON; 2014.
129. Mylan Pharmaceuticals Inc: **Mercaptopurine**. In: *US Product Monograph*. Morgantown, WV; 2022.
130. Quinn Pharmaceuticals LLC: **Mercaptopurine**. In: *US Product Monograph*. Coral Springs, Florida; 2020.
131. Mylan Pharmaceuticals Inc: **Mercaptopurine**. In: *US Product Monograph*. Morgantown, WV; 2019.
132. Pfizer Canada ULC: **Methotrexate**. In: *CA Product monograph*. Kirkland QC; 2019.
133. Medexus Inc: **Metobject Subcutaneous (methotrexate)**. In: *CA Product Monograph*. Bolton, ON; 2019.
134. Accord Healthcare Inc: **Methotrexate**. In: *US Product Monograph*. Durham, NC; 2021.

135. Feuerstein JD, Ho EY, Shmidt E, Singh H, Falck-Ytter Y, Sultan S, Terdiman JP, Sultan S, Cohen BL, Chachu K *et al*: **AGA Clinical Practice Guidelines on the Medical Management of Moderate to Severe Luminal and Perianal Fistulizing Crohn's Disease**. *Gastroenterology* 2021, **160**(7):2496-2508.
136. Accord Healthcare Inc: **ACH-Methotrexate**. In: *CA Product Monograph*. Kirkland QC; 2022.
137. Antares Pharma Inc: **Otrexup (methotrexate)**. In: *US Product Monograph*. Ewing, NJ; 2019.
138. Medexus Pharma Inc: **Rasuvo (methotrexate)**. In: *US Product Monograph*. Chicago, IL; 2020.
139. Alvogen Inc: **Methotrexate**. In: *US Product Monograph*. Morristown, NJ; 2022.
140. Apotex: **Methotrexate**. In: *Health Canada Product monograph*. Toronto ON; 2019.
141. Teva Women's Health Inc: **Methotrexate**. In: *FDA Product monograph*. 2018.
142. Canadian Rheumatology Association: **Canadian Rheumatology Association Recommendations for Pharmacological Management of Rheumatoid Arthritis with Traditional and Biologic Disease-modifying Antirheumatic Drugs** In: *The Journal of Rheumatology* vol. 38; 2011: 1-24.
143. Committee BCGaPA: **Rheumatoid Arthritis: Diagnosis, Management and Monitoring**. 2012.
144. AbbVie Corporation: **Humira (adalimumab)**. In: *CA Product Monograph*. St-Laurent, QC; 2021.
145. Amgen Canada Inc: **Amgevita**. In: *CA Product Monograph*. Mississauga, ON; 2021.
146. Organon Canada Inc: **Hadlima (adalimumab biosimilar)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
147. Pfizer Canada ULC: **Abrilada (adalimumab)**. In: *CA Product Monograph*. Kirkland, QC; 2021.
148. Sandoz Canada Inc: **Hyrimoz (Adalimumab Injection)**. In: *CA Product Monograph*. Boucherville, QC; 2021.
149. BGP Pharma ULC: **Hulio (Adalimumab injection)**. In: *CA Product Monograph*. Etobicoke, ON; 2022.
150. Fresenius Kabi Canada Ltd: **Indacio (adalimumab)**. In: *CA Product Monograph*. Toronto, ON; 2020.
151. Celltrion Healthcare Canada Limited: **Yuflyma (adalimumab)**. In: *CA Product Monograph*. South Waterloo, ON; 2021.
152. Jamp Pharma Corporation: **Simlandi (adalimumab)**. In: *CA Product Monograph*. Boucherville, QC; 2022.
153. AbbVie Inc: **Humira (adalimumab)**. In: *US Product Monograph*. North Chicago, IL; 2021.
154. Amgen Inc: **Amjevita (adalimumab-atto)**. In: *US Product Monograph*. Thousand Oaks, CA; 2022.
155. Organon & Co: **Hadlima (adalimumab-bwwd)**. In: *US Product Monograph*. Jersey City, NJ; 2022.
156. Pfizer Inc: **Abrilada (adalimumab-afzb)**. In: *US Product Monograph*. New York, NY; 2022.

157. Sandoz Inc: **Hyrimoz (adalimumab-adaz)**. In: *US Product Monograph*. Princeton, NJ; 2022.
158. Boehringer Ingelheim Pharmaceuticals Inc: **Cyltezo (adalimumab-adbm)**. In: *US Product Monograph*. Ridgefield, CT; 2021.
159. Mylan Pharmaceuticals Inc: **Hulio (adalimumab-flkjp)**. In: *US Product Monograph*. Morgantown, West Virginia; 2022.
160. AbbVie Corporation: **Humira (Adalimumab)**. In: *CA Product Monograph*. QC, Canada; 2019.
161. AbbVie Inc: **Humira (adalimumab)**. In: *US Product Monograph*. North Chicago, IL; 2020.
162. Samsung Bioepis: **Hadlima (adalimumab biosimilar)**. In: *CA Product Monograph*. Cheomdan-daero, Yeonsu-gu, Incheon; 2019.
163. Pfizer Inc: **Abrilada (adalimumab-afzb)**. In: *US Product Monograph*. New York, NY; 2019.
164. Amgen Inc: **Amjevita (adalimumab-atto)**. In: *US Product Monograph*. Thousand Oaks, CA; 2019.
165. Boehringer Ingelheim Pharmaceuticals Inc: **Cyltezo (adalimumab-adbm)**. In: *US Product Monograph*. Ridgefield, CT; 2019.
166. Samsung Bioepis Co: **Hadlima (adalimumab-bwwd)**. In: *US Product Monograph*. Cheomdan-daero, Yeonsu-gu, Incheon; 2019.
167. Sandoz Inc: **Hyrimoz (adalimumab-adaz)**. In: *US Product Monograph*. Princeton, NJ; 2018.
168. Mylan Pharmaceuticals Inc: **Hulio (adalimumab-flkjp)**. In: *US Product Monograph*. Morgantown, West Virginia; 2020.
169. UCB Canada Inc: **Cimzia (certolizumab)**. In: *CA Product Monograph*. Oakville, ON; 2019.
170. UCB Inc: **Cimzia (certolizumab)**. In: *US Product Monograph*. Smyrna, GA; 2021.
171. UCB Inc: **Cimzia (certolizumab)**. In: *US Product Monograph*. Smyrna, GA; 2019.
172. Janssen Inc: **Remicade (infliximab)**. In: *CA Product Monograph*. Toronto, Ontario; 2021.
173. Limited CHC: **Inflectra (infliximab)**. In: *CA Product Monograph*. Waterloo, ON; 2021.
174. Merck Canada Inc: **Renflexis (infliximab)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
175. ULC PC: **Inflectra (infliximab)**. In: *CA Product Monograph*. Kirkland, QC; 2020.
176. Amgen Canada Inc: **Avsola (infliximab)**. In: *CA Product Monograph*. Mississauga, ON; 2022.
177. Janssen Biotech Inc: **Remicade (infliximab)**. In: *US Product Monograph*. Horsham, PA; 2022.
178. Organon LLC: **Renflexis**. In: *US Product Monograph*. Jersey City, NJ; 2022.

179. Pfizer Laboratories Div Pfizer Inc: **Inflectra (infliximab-dyyb)**. In: *US Product Monograph*. New York, NY; 2022.
180. Amgen Inc: **Avsola (infliximab-axxq)**. In: *US Product Monograph*. Thousand Oaks, CA; 2021.
181. Pfizer Ireland Pharmaceuticals: **Ixifi (infliximab-qbtx)**. In: *US Product Monograph*. Ringaskiddy, Co Cork; 2020.
182. Janssen Inc: **Remicade (infliximab)**. In: *CA Product Monograph*. Toronto, Ontario; 2019.
183. Janssen Biotech Inc: **Remicade (infliximab)**. In: *US Product Monograph*. Horsham, PA; 2020.
184. Samsun Bioepis Co Ltd: **Renflexis (infliximab-abda)**. In: *US Product Monograph*. Yeonsu-gu, Incheon; 2020.
185. Celltrion Inc: **Inflectra (infliximab-dyyb)**. In: *US Product Monograph*. Yeonsu-gu, Incheon; 2019.
186. Amgen Canada Inc: **Avsola (infliximab)**. In: *CA Product Monograph*. Mississauga, ON; 2020.
187. Celltrion Healthcare Co Ltd: **Inflectra (infliximab)**. In: *CA Product Monograph*. Yeonsu-gu, Incheon; 2019.
188. Amgen Inc: **Avsola (infliximab-axxq)**. In: *US Product Monograph*. Thousand Oaks, CA; 2019.
189. Pfizer Ireland Pharmaceuticals: **Ixifi (infliximab-qbtx)**. In: *US Product Monograph*. Ringaskiddy, Co Cork; 2017.
190. Takeda Canada Inc: **Entyvio (vedolizumab)**. In: *CA Product Monograph*. Toronto, ON; 2021.
191. Takeda Pharmaceuticals America Inc: **Entyvio (vedolizumab)**. In: *US Product Monograph*. Lexington, MA; 2021.
192. Takeda Canada Inc: **Entyvio (vedolizumab)**. In: *CA Product Monograph*. Oakville, Ontario; 2019.
193. Takeda Pharmaceuticals America Inc: **Entyvio (vedolizumab)**. In: *US Product Monograph*. Deerfield, Illinois; 2020.
194. Janssen Inc: **Stelara (ustekinumab)**. In: *CA Product Monograph*. Toronto, Ontario; 2021.
195. Janssen Biotech Inc: **Stelara (ustekinumab)**. In: *US Product Monograph*. Horsham, PA; 2022.
196. Janssen Inc: **Stelara (ustekinumab)**. In: *CA Product Monograph*. Toronto, Ontario; 2020.
197. Janssen Biotech Inc: **Stelara (ustekinumab)**. In: *US Product Monograph*. Horsham, Pennsylvania; 2020.